Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 63.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,693 shares of the company’s stock after purchasing an additional 21,579 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Mirum Pharmaceuticals were worth $5,145,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC grew its stake in shares of Mirum Pharmaceuticals by 21.4% during the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares in the last quarter. Vanguard Group Inc. raised its stake in Mirum Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock valued at $205,065,000 after buying an additional 50,720 shares in the last quarter. State Street Corp lifted its holdings in Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after buying an additional 797,088 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Mirum Pharmaceuticals by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock valued at $112,196,000 after acquiring an additional 137,087 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Mirum Pharmaceuticals by 56.6% during the 4th quarter. Wellington Management Group LLP now owns 1,237,830 shares of the company’s stock worth $97,776,000 after acquiring an additional 447,141 shares in the last quarter.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 20,000 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $122.27, for a total transaction of $2,445,400.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $23,758,161.43. This represents a 9.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00. Following the completion of the sale, the chief financial officer owned 42,181 shares of the company’s stock, valued at $5,156,627.25. This trade represents a 10.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,155 shares of company stock valued at $7,185,662 over the last three months. 8.32% of the stock is currently owned by company insiders.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of approximately $176.2 million, ahead of the $166.3 million analyst consensus and up 37.9% year over year. Growth from Livmarli and other bile-acid medicines supported the performance. Mirum Q2 earnings and 2026 outlook
• Positive Sentiment: The company raised its 2026 revenue guidance to $680 million-$700 million, above the roughly $675.1 million consensus estimate, reinforcing expectations for continued product-driven growth.
• Positive Sentiment: Despite reducing their targets, TD Cowen and HC Wainwright maintained “buy” ratings at $140, while Citizens JMP kept a “market outperform” rating with a $137 target. These targets imply substantial potential upside from recent trading levels. Analyst price target updates
• Neutral Sentiment: Analysts continue to view Mirum favorably overall, but the target reductions—from as high as $185 previously—indicate that near-term risks and valuation assumptions have become more cautious.
• Negative Sentiment: Citizens warned that the FDA made an “unexpected” request for an additional Phase 3 study, clouding Mirum’s near-term outlook. The request raises potential development costs and could delay regulatory progress, which was the primary catalyst behind the selloff. Citizens FDA assessment
• Negative Sentiment: Second-quarter earnings missed expectations: Mirum reported a larger-than-expected per-share loss, while the loss widened from the prior-year period. The company remains unprofitable, increasing investor sensitivity to clinical spending and regulatory delays. Mirum quarterly earnings report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734 under a pre-arranged Rule 10b5-1 plan. The scheduled nature limits its significance, but the transaction reduced her direct holdings by about 59%. Mirum insider sale

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Robert W. Baird set a $123.00 price target on Mirum Pharmaceuticals in a report on Thursday. HC Wainwright cut their price objective on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a report on Thursday. Citizens Jmp lowered their target price on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a report on Thursday. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. Finally, Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $137.33.

Mirum Pharmaceuticals Stock Down 11.0%

MIRM opened at $94.11 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $54.74 and a 52 week high of $130.00. The business has a 50 day moving average price of $110.35 and a two-hundred day moving average price of $101.79. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The company has a market cap of $5.74 billion, a PE ratio of -6.47 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The company had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 26.88%. The company’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.12) earnings per share. As a group, research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.